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ABSTRACT
Population- level biomedical research offers new 
opportunities to improve population health, but also 
raises new challenges to traditional systems of research 
governance and ethical oversight. Partly in response to 
these challenges, various models of public involvement 
in research are being introduced. Yet, the ways in which 
public involvement should meet governance challenges 
are not well understood. We conducted a qualitative 
study with 36 experts and stakeholders using the World 
Café method to identify key governance challenges 
and explore how public involvement can meet these 
challenges. This brief report discusses four cross- cutting 
themes from the study: the need to move beyond 
individual consent; issues in benefit and data sharing; the 
challenge of delineating and understanding publics; and 
the goal of clarifying justifications for public involvement. 
The report aims to provide a starting point for making 
sense of the relationship between public involvement 
and the governance of population- level biomedical 
research, showing connections, potential solutions 
and issues arising at their intersection. We suggest 
that, in population- level biomedical research, there 
is a pressing need for a shift away from conventional 
governance frameworks focused on the individual and 
towards a focus on collectives, as well as to foreground 
ethical issues around social justice and develop ways to 
address cultural diversity, value pluralism and competing 
stakeholder interests. There are many unresolved 
questions around how this shift could be realised, but 
these unresolved questions should form the basis for 
developing justificatory accounts and frameworks for 
suitable collective models of public involvement in 
population- level biomedical research governance.
Population- level biomedical research involving 
large- scale biobanks, genetic data repositories 
and digital records offers new opportunities to 
improve population health, but also raises new 
challenges to traditional systems of research gover-
nance and ethical oversight. This is in particular 
because conventional models of informed consent 
and ethics review are unable to account for long- 
term storage, sharing and linkage, and use of data 
for future unspecified research.1–4 Public concerns 
regarding the extent to which research institutions 
can be trusted to handle data ethically have contrib-
uted to a ‘crisis in trust’ in biomedical research.5 6
Partly in response to these concerns, various 
models of public involvement in population- level 
biomedical research initiatives are being intro-
duced.2 7–11 However, while public involvement is 
generally seen as a way to foster public trust, over-
come barriers to individual consent, encourage 
accountable and responsible research, and address 
other ethical issues, the ways in which public involve-
ment can or should meet these challenges are often 
unarticulated and poorly defined. Although it is 
increasingly agreed that we have reasons to support 
public involvement in population- level biomedical 
research, it is often unclear what those reasons 
are and how they connect with the challenges that 
involvement is intended to address. This lack of a 
normative framework for public involvement in 
governance poses a further barrier to addressing 
the concerns identified. It is clear that population- 
level biomedical research requires a shift in ethical 
thinking, compared with other forms of biomedical 
research that have focused more on the individual, 
towards new approaches to governance that can 
better account for the collective concerns and inter-
ests involved.
To explore these issues and areas of uncertainty, 
we convened the Public Involvement and Gover-
nance in Population- Level Biomedical Research 
workshop in Oxford, UK in January 2020. The 
workshop brought together an international, inter-
disciplinary and cross- sectoral group of 36 partic-
ipants with expertise and stakes in relevant issues 
from different perspectives, including senior and 
emerging academic specialists, patient and public 
involvement professionals and patient advocates. 
Invitations were sent directly to several stakeholders 
and information about the event was also circulated 
online, so that those interested, but unknown to us, 
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could register and attend. As part of the workshop, we conducted 
a study using the World Café method, which is a group dialogue 
method that facilitates knowledge synthesis via group conversa-
tion and exchange of information and experiences, enabling the 
generation of a great deal of data in a relatively short amount 
of time.12 Our World Café consisted of several rounds of small 
group table discussions, each focused on a different but related 
topic and involving a facilitator who also took notes on spread-
sheets. Following small group discussions, all participants came 
together for a general discussion where overarching themes 
across the discussions were identified and evaluated.
The participants were asked to identify and discuss, first, 
key governance challenges in biomedical research involving 
biobanks, genetic repositories and digital databases, and, second, 
possibilities of public involvement in this mode of research and 
how involvement should be fostered, if at all.
The World Café generated 36 sheets of notes, which were 
subjected to qualitative thematic analysis, where the data were 
first analysed independently by four members of the research 
team, who then came together to merge the analyses and iden-
tify the most prominent cross- cutting themes. The findings 
and conclusions were then circulated to, and confirmed and 
approved by, all participants. This brief report discusses these 
four cross- cutting themes: the need for (1) moving beyond indi-
vidual consent; (2) issues in benefit and data sharing; (3) delin-
eating and understanding publics; and (4) clarifying justifications 
for public involvement.
MOVING BEYOND INDIVIDUAL CONSENT
A major theme in the discussions was informed consent, which 
has arguably been the dominant ethical doctrine in research 
involving humans.13 Participants expressed concern about 
the ‘consent obsession’ suggesting that the traditional focus 
on consent is inappropriate in the context of population- level 
research. Participants highlighted the fact that existing consent 
models generally focus on individual rather than community or 
group consent. Ethical and governance challenges in population- 
level research, however, go beyond individual concerns and 
single research initiatives, raising the possibility of community 
or group harm.14 15
Many participants agreed that, as research gets bigger, 
involving larger amounts of linked population- level data, indi-
vidual consent for population- level research is neither sufficient 
nor central to appropriate governance. A shift is needed to 
refocus both the theory and practice of research ethics oversight 
to suit the contemporary landscape of population- level research. 
Participants suggested that it is no longer sufficient to concep-
tualise research subjects as individuals taking part in research; 
instead, the subjects should be understood to be groups and 
communities, and attention should be paid to the social contexts 
in which the members of these groups live and the diverse inter-
ests they may express in relation to population- level biomedical 
research.
ISSUES IN BENEFIT AND DATA SHARING
Population- level biomedical research raises tensions, not just 
between individual versus collective interests, but also between 
different collective interests: for example, a community that has 
donated samples to a biobank versus the commercial entity that 
runs the biobank. In the context of enduring systemic national 
and global health inequities, participants repeatedly highlighted 
the importance of benefit sharing and priority setting. Some 
participants suggested that because biomedical ethics has focused 
on protecting research participants (ie, mitigating the risks of 
research), the focus should now be redirected more towards 
what can be done for communities that engage in research. The 
mechanisms to enable benefit sharing were widely debated, espe-
cially in contexts where commercial interests are closely tied to 
research outputs: one role for public involvement could be to 
provide input into how benefits ought to be shared with partic-
ular communities.
Social justice and data sharing were also tied to practical ques-
tions around resources, management and curation. Population- 
level biomedical research initiatives often rely on data sharing 
including across national and regional borders, but the regu-
latory frameworks in different national and regional contexts 
are diverse and requirements for accessing different databases, 
depositories and biobanks are inconsistent, presenting barriers 
to data linkage and collaborations. Some participants noted that 
there can be ‘gatekeeping’ behaviours around databases that 
result, among other things, from the conflicting interests and 
priorities of the various stakeholders in these research initiatives. 
In this context, it is unclear who should decide on data access 
and for what purposes it can be used.
DELINEATING AND UNDERSTANDING PUBLICS
Although there has been a shift away from singular conceptualisa-
tions of ‘the public’ towards recognition of publics as plural,16 17 
some participants observed that further scrutiny of the notion of 
‘publics’ is also needed: which public(s) matter, when and why? 
This is connected with the question of the meaning and nature 
of ‘public interest’ and ‘public benefit’. While these notions are 
often invoked and circulate in discussions and debates around 
research governance and public involvement, they are often 
poorly defined and rarely conceptually unpacked: as different 
individuals and social groups have different interests, diverse 
needs and perspectives on biomedical research and how it 
should be governed; it is unclear whose interests should count as 
‘public’ interests, who benefits when ‘public benefits’ are distrib-
uted and who can legitimately answer these questions.
Participants observed that there is a need to generate better 
mechanisms for public involvement in population- level health 
research. Although such mechanisms have been developed at 
the level of individual research initiatives (eg, public delibera-
tion methods), there are currently few governance mechanisms 
for making decisions collectively at a wider population level. 
Some participants observed that there are unresolved tensions 
between the centralisation of governance and local needs: high- 
level governance mechanisms aim to be impartial and universal, 
whereas local priorities and needs often require partial rather 
than equal benefit sharing.
DISTINGUISHING JUSTIFICATIONS FOR PUBLIC INVOLVEMENT
Despite a clear trend toward public involvement in the gover-
nance of population- level research, there remains a great deal of 
uncertainty and opacity about why public involvement should 
be undertaken.
In particular, ‘legitimacy’ was a noteworthy focus of discus-
sion. Participants distinguished between descriptive and norma-
tive uses of the concept18: in practice, public involvement may 
be undertaken to increase public acceptance or to promote a 
more favourable perception of research, which would provide 
‘descriptive legitimacy’, but does not necessarily ensure ‘norma-
tive legitimacy’. The general feeling of the discussion was that 
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public involvement strategies should aim at normative legiti-
macy: involving the public for reasons other than the manage-
ment of perception. Participants proposed a variety of justifying 
reasons, including: to understand public expectations, inform 
research initiatives or to ensure that research is conducted ‘in 
the right way’. All of these were contested, and no single justifi-
cation prevailed, and each raised further questions.
Participants also discussed transparency and public trust in 
research as an important justification for public involvement. In 
this context, trust was distinguished from trustworthiness19–21: 
public trust may be gained through public involvement, but the 
research institution may not be trustworthy. This was impor-
tantly seen as mapping onto the distinction between the descrip-
tive and the normative senses of legitimacy: by ensuring that they 
were trustworthy, research institutions were in this sense demon-
strating their normative legitimacy.
Another relevant distinction, within the idea of normative 
legitimacy, was between intrinsic and extrinsic (or outcome- 
oriented) justifications for public involvement. Extrinsic justi-
fications focus on the ways in which public involvement can 
facilitate ‘better’ research outcomes, whereas intrinsic justi-
fications focus on the research process and the role of public 
involvement in making the process ‘right’.22 However, while this 
distinction was seen as useful by many participants, their sepa-
ration in practice looked difficult because the two rationales are 
often intertwined: public involvement in the research process 
may be valuable in its own right and enable better outcomes.
With this set of rationales for public involvement in play, it 
was apparent across the conversations that there is a need for 
more conceptual clarity about them and their application to 
specific publics, as well as how different involvement methods 
should map onto those justifications and how such methods 
should be evaluated.
CONCLUSION
Our aim in this report has been to provide a starting point for 
developing a more systematic ethical approach to the relation-
ship between public involvement and governance in population- 
level biomedical research, showing connections, potential 
solutions and issues arising at their intersection. We acknowl-
edge that there are vast literature on public involvement in 
health research, democratic deliberation and participation, and 
public engagement in decision- making, and we do not claim that 
our findings provide a comprehensive account of the governance 
challenges and justifications for public involvement. They do, 
however, indicate that embedding involvement in the gover-
nance of population- level biomedical research may require a 
novel approach. Our findings revealed how, in population- level 
research in particular, there is a pressing need for a shift away 
from conventional governance frameworks that are focused on 
the individual as the subject of rights, risks and benefits, and 
towards a focus on the collective, both in terms of foregrounding 
ethical issues connected with social justice, and in terms of 
developing ways to address cultural diversity, value pluralism 
and competing stakeholder interests. Existing perspectives from 
political theory and social science on public involvement and 
democratic participation could be usefully drawn on to inform 
further analysis on these issues. There are many unresolved ques-
tions around how this shift can or should be realised in theory 
and practice, including how consent should be re- conceptual-
ised, the justifications for public involvement in research and 
how they map onto distinct mechanisms of involvement, how 
benefits should be distributed and different interests prioritised, 
and who should decide how these questions are answered. 
These questions should be taken up by those seeking to develop 
accounts and frameworks of public involvement in the gover-
nance of population- level biomedical research.
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 12 Brown J, Isaacs D. The world Café: a resource guide for hosting conversations that 
matter. Berrett- Koehler Publishers, 2005.
 13 Manson NC, O’Neill O. Rethinking informed consent in bioethics. Cambridge 
Univeristy Press, 2007.
 14 Koenig BA. Have we asked too much of consent? Hastings Cent Rep 
2014;44(4):33–4.
 15 Grande D, Mitra N, Shah A, et al. The importance of purpose: moving beyond 
consent in the societal use of personal health information. Ann Intern Med 
2014;161(12):855–62.
 16 Felt U, Fochler M. Machineries for making publics: inscribing and de- scribing publics 
in public engagement. Minerva 2010;48(3):219–38.
 17 Hull SC, Wilson Diné DR. Beyond Belmont: ensuring respect for AI/AN communities 
through tribal IRBs, laws, and policies. Am J Bioeth 2017;17(7):60–2.
 18 Buchanan A, Keohane RO. The legitimacy of global governance institutions. Ethics Int 
Aff 2006;20(4):405–37.
 19 O’Neill O. Autonomy and trust in bioethics. Cambridge University Press, 2002.
 20 O’Neill O. Linking trust to Trustworthiness. Int J Philos Stud 2018;26(2):293–300.
 21 Hawley K. Trustworthy Groups and Organisations. In: Faulkner P, Simpson T, eds. The 
philosophy of trust. Oxford University Press, 2017: 230–50.
 22 McCoy MS, Warsh J, Rand L, et al. Patient and public involvement: two sides of the 
same coin or different coins altogether? Bioethics 2019;33(6):708–15.
 o
n
 O
ctober 9, 2020 by guest. Protected by copyright.
http://jme.bmj.com/
J M
ed Ethics: first published as 10.1136/m
edethics-2020-106530 on 6 O
ctober 2020. Downloaded from
 
